Health care stocks were leaning lower premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was down 0.7% and the iShares Biotechnology ETF (IBB) was inactive.
Marinus Pharmaceuticals (MRNS) soared 43% after it said it signed a deal under which Immedica Pharma will acquire all of its issued and outstanding shares for $0.55 a share.
Axsome Therapeutics (AXSM) said Monday it has met the primary endpoint in its ACCORD-2 phase 3 trial of AXS-05, which is intended for Alzheimer's disease agitation, but failed to achieve statistical significance for its primary endpoint in another trial. Axsome shares slid 7.1%.
Precigen (PGEN) said Monday it has completed a rolling biologics license application submission to the US Food and Drug Administration for PRGN-2012, a treatment for recurrent respiratory papillomatosis in adults. Precigen shares rose 12.8%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。